WO2003094935A1 - Utilisation de la kininogenase urinaire humaine dans la fabrication d'un medicament pour le traitement et la prevention de l'embolie cerebrale - Google Patents
Utilisation de la kininogenase urinaire humaine dans la fabrication d'un medicament pour le traitement et la prevention de l'embolie cerebrale Download PDFInfo
- Publication number
- WO2003094935A1 WO2003094935A1 PCT/CN2003/000345 CN0300345W WO03094935A1 WO 2003094935 A1 WO2003094935 A1 WO 2003094935A1 CN 0300345 W CN0300345 W CN 0300345W WO 03094935 A1 WO03094935 A1 WO 03094935A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- human
- use according
- brain
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to a new use of biochemical substances in pharmaceutical engineering. More specifically, the use of human urinary kininogenase in the preparation of a medicament for the treatment and prevention of cerebral infarction. Background technique
- the present invention provides the use of human urokininogenase for the preparation of a medicament for the treatment and prevention of cerebral infarction.
- Human urokininogenase is a glycoprotein naturally present in human urine with a molecular weight of approximately 54,000 Daltons (gel filtration method), which is a single chain consisting of 238 amino acid residues, N The terminal and C-terminal amino acid residues are isoleucine and serine, respectively, and the molecule contains 5 pairs of S-S bonds, respectively Cys7-Cysl50, Cys26-Cys42, Cys29-Cysl96, Cysl61_Cysl75 and Cysl86-Cys211, etc.
- the electrical point is approximately 4.0.
- the molecule contains 14.4% sugar, and the binding sites are located at Asn78, Asn84 and Asnl41, respectively.
- the sugar composition is 3% mannose, 1.7% galactose, 0.8% fucose, and 5.0% N-acetylglucosamine.
- Primary structure (amino acid composition sequence) Ile-Val-Gly-Gly-Trp-Glu-Cys-.Glu-Gln-His-Ser-Gln-Pro-Trp-Gln-Ala-Ala-Leu-Tyr-His-
- a human urokininogenase is used as an active ingredient in combination with a pharmaceutically acceptable carrier to prepare an injection for the treatment and prevention of cerebral infarction.
- Urine male fresh urine is preferred
- DEAE-Sepharose column equilibrated with 0.05 M Na2HPO4-NaH2PO4, O.lM NaCl, pH 7.4 buffer.
- the concentrated urine was applied to a DEAE-Sepharose column, rinsed with an equilibration buffer, and eluted with a buffer of 0.05 M Na2HP04-NaH2P04, 0.3 M NaCl, pH 7.4, and the eluted peak was collected; the Aprotinin-Sepharose column was passed through 0.05 M Na2HP04- NaH2P04, equilibrated buffer equilibration at pH 8.0, adjusted to pH 8.0 on the DEAE-Sepharose column and applied to the Aprotinin-Sepharose column with equilibration buffer The solution was washed with 0.1 M HAc-NaAc, pH 4.0 buffer to collect the elution peak; Aprotinin-Sepharose column elution peak was dialyzed against 0.05 M Na2HP04-NaH2P04, 0.1 M NaCl, pH 7.0.
- the purified human urokininogen can be mixed with a pharmaceutically acceptable carrier to produce a plurality of dosage forms of the drug.
- Said pharmaceutical carrier comprises pharmaceutically acceptable diluents, stabilizers, excipients such as glycine, mannitol, pH 7.0 phosphate buffer solution, albumin, dextran, glucose, lactose, sodium chloride, sorbitol, citric acid , gelatin, water for injection, physiological saline, etc., one or more of them may be used at the same time.
- a preferred combination is glycine, mannitol, pH 7.0 phosphate buffer solution.
- the medicament of the present invention can be prepared into a dosage form suitable for intravenous injection, intramuscular injection or subcutaneous injection, and includes a dosage form such as a powder needle, a water needle, and an infusion solution.
- Preferred modes of administration are intravenous drip and I or intravenous bolus.
- the effective amount of the drug is in the range of 0.0001 to 0.05 PNA/kg body weight, and the preferred amount is 0.002 to 0.011 PNA/kg body weight.
- the dosage form of the powder or water needle or infusion preparation is 0.1 to 0.2 PNA units per bottle, and the preferred specification is 0.15 PNA unit / tube (bottle).
- PNA is defined as: 1 hour of hydrolysis of the substrate Val-Leu-Axg-PNA releases 1 ⁇ mol of free PNA at 37 ° C, pH 8.0, which is 1 PNA unit.
- the right femoral artery was cannulated into the abdominal aorta, and the cannula was connected to the transducer through a three-way needle, and a physiological polygraph was used to monitor blood pressure and a blood reservoir (height 40 mmHg, ie, 54.4 cm H 2 0 column).
- the bilateral common carotid arteries were separated and threaded for use. Stable for 30 minutes after surgery. Open the three-way needle to the blood reservoir for rapid exsanguination for about 1 ⁇ 2 minutes, up to 40mmHg, and clamp the bilateral common carotid arteries with arterial clips. After 10 minutes, quickly release the bilateral arterial clips, and pressurize about 350mmHg.
- the blood in the blood reservoir was injected back into the body (about 2 minutes) while oxygen was taken for 30 minutes. Then the ear veins were instilled with the following different drugs, the volume was about 2.5ml/kg, the infusion was maintained for 30 minutes, the arterial cannula was removed, and the incision was sutured. The words were fed separately, and then intravenously infused different doses according to the following grouping. Human urinary kininogenase or control for three consecutive days.
- I/R Ischemic control group
- PGEj group PGEj 300ug/kg
- Brain water content (wet weight to dry weight) / wet weight X 100%. Then, using dry specimens, the content of Na+ and Ca 2+ was measured after acid digestion (determined by atomic absorption spectrophotometry). The latter part of the left hemisphere was rapidly placed at -196 °C for liquid nitrogen freezing to measure MDA (thiobarbituric acid method), cAMP (cyclic adenosine) and cGMP (cyclophosphanoguanine).
- MDA thiobarbituric acid method
- cAMP cyclic adenosine
- cGMP cyclophosphanoguanine
- the ATP HPLC method
- the ATP was measured by liquid nitrogen freezing in the first half of the right hemisphere.
- the second half was placed in 10% formalin solution, sectioned, HE stained, and light microscopy.
- the test results were expressed as mean soil standard deviation (X-S SD), and the q-test between groups of variance analysis was statistically processed.
- I layer molecular layer
- II layer outer layer
- the ischemic/reperfusion group could not distinguish the layer II, the group II layer and the layer III were unclear, and the human urokinin group I and the human urokininogen group II group II were more obvious.
- About 1/10 of the leather is thick.
- Layer III outer cone layer: This layer is not obvious in the ischemia/reperfusion group, PGE ⁇ fi is thin, and there are pyramidal cells. Human urokinin group I and human urokininogen group II were thicker and had pyramidal cells.
- IV layer inner layer: There was no significant difference between the groups.
- V layer inner cone layer: The thickness is about 1/5 of the cortex, and there are large pyramidal cells, and there is no difference between the groups.
- VI layer multi-type layer: There is no difference between the groups.
- Increased brain water content is an important indication of cerebral edema. Na+ water retention in brain cells after brain tissue injury. Therefore, it is generally considered that Na + is increased in brain tissue after edema, and K + is decreased. Cerebral ischemia and hypoxia cause cell membrane lipid peroxidation, and cell membrane permeability increases, causing intracellular enzymes to leak out. Therefore, brain cells LDH and CPK increased blood, and cerebral venous blood LDH and CPK activity increased.
- kallikrein human urokininogenase not only exerts its effects through its dilation of blood vessels, but also exerts its anti-rabbit cerebral ischemia/reperfusion injury recovery process through the interaction of renin-angiotensin system. effect.
- the tracheal intubation respirator controls the breathing, and 1000 u/kg heparin is intravenously injected into the anticoagulation.
- the right femoral artery was cannulated into the abdominal aorta, the cannula was connected to the transducer through a three-way needle, and the physiological multi-channel was connected to monitor blood pressure.
- the blood reservoir was connected (height 40 mmHg, ie 54.4 cm H 2 0 column), right The femoral vein was cannulated for drug delivery.
- the bilateral common carotid arteries were separated for use. After 30 minutes of stabilization, the three-way needle was opened to quickly bleed to the blood reservoir (about 1 to 2 minutes, reaching 40 mmHgBP), and the common carotid artery was clamped with an arterial clip. After 10 minutes, the bilateral arterial clips were quickly released, and the blood in the blood reservoir was injected into the body (about 2 minutes) with pressure (about 300 mmHg), while oxygen was absorbed. Check the experiment for 30 minutes.
- the experimental animals were divided into the following four groups, and different doses of human urokininogenase or reference substance (capacity 2.5 ml/kg PBS) were instilled 10 minutes before cerebral ischemia, and the perfusion was maintained for 30 minutes, after the instillation was completed 10 End the experiment in minutes.
- Nicardipine group 10ug/kg
- the arterial cannula was bled, blood samples were taken, plasma was separated by centrifugation, and blood glucose, lactate, LDH activity, and MDA content were measured.
- the whole brain was removed, and the left hemisphere was quickly frozen with liquid nitrogen.
- the first half was ground with liquid nitrogen and homogenized with 6% trichloroacetic acid to determine the ATP content of the tissue.
- the first half of the right hemisphere is weighed and weighed at 90 °C. After drying thoroughly, the dry weight is measured. The tissue/dry weight ratio is calculated to reflect the degree of brain edema.
- the posterior half of the right hemisphere of the brain was prepared with PBS (1: 10 W/V), and the tissue MDA content was determined by thiobarbituric acid.
- the mortality of the animals in each group was 4/10 in the ischemic control group, 4/10 in the human urokininogen group I, and 3/10 in the human urokininogenase group.
- the above indicators increased by 46.46%, 211.45%, 60.79%, and 397.13% (P values were all less than 0.01).
- Cerebral ischemia/reperfusion injury in comparison with sham operation group, brain tissue ATP content decreased (-74.71%, P ⁇ 0.01), brain tissue edema (wet weight/dry weight ratio increased by 36.71%, P ⁇ 0.01) and brain MDA production increased (+52.83%, P ⁇ 0.01).
- the treatment groups showed different degrees of improvement (respectively in each group), reduced brain ATP content (PO.01), human urokininogenase group was superior to human urokininogenase I group (P ⁇ 0.01), wet The weight/dry weight ratio of each group was slightly lower than that of the ischemic control group, but it was not statistically significant (P>0.05).
- the human urokininogenase group was more effective than the ischemic control group, human urokininogen group I and Nicardipine group (P ⁇ 0.05). Inhibition of MDA production in brain tissue was only statistically significant between the human urokininogen group and the ischemic control group (PO.05), between the human urokininogen group and the human urokininogenase I group and the Nicardipine group. The difference was also significant (P ⁇ 0.05).
- a human urinary kallikrein group I 2.0X 10- 3 PNA / kg
- a human urinary kallikrein ⁇ group 10.0 X 10- 3 PNA / kg 5.
- PGE, (prostaglandin) group 300ug/kg
- Oral group 2 hours before surgery, oral administration once a day, 56u/kg
- Infarct size In this study, arachidonic acid was injected into the internal carotid artery to cause extensive infarction in the brain. The infarction group accounted for one-third of the total brain area. Treatment of each group of preventive drug administrations reduced the infarct size of the model (p ⁇ 0.01 compared with the infarct group). The order of strength was human urokininogenase II, human urinary kininogenase ⁇ / ⁇ group, PG ⁇ group, oral group and human urokininogen group I. The area of cerebral infarction in human urinary kininogenase group II was only 39.72% of the infarct size of the infarcted group, and the effect of reducing infarct size was significantly stronger than that of other treatment groups.
- Plasma MDA content The mechanism of AA-induced infarction includes various mechanisms such as stimulating vasospasm, damaging the vascular endothelium, and promoting platelet activation and aggregation. Among them, AA promoted lipid peroxidation and determined the content of MDA in the final product.
- the infarction group increased by 2.4 times (p ⁇ 0.01) compared with the sham operation group. In the treatment group, except for the oral group, there was no significant effect (p>0.05), human urokininogenase I group, human urokininogen group II, human urokininogenase I/II group and PGE group.
- Plasma LDH activity Infarcted tissue ischemic injury, cytosolic enzyme LDH leaks out into the blood circulation.
- the plasma LDH activity in the infarct group was approximately 3 times higher than that in the sham operation group (p ⁇ 0.01).
- the plasma LDH activity in the oral group was slightly lower than that in the infarct group, but the difference was not statistically significant (p>0.05); human urokininogenase I group, human urokininogen group II, human urinary kininogenase I / Plasma LDH activity was lower in the sputum group and the PGE _& infarct group by 14.745% (p ⁇ 0.05), -15.77% (p ⁇ 0.05), -24.23% (p ⁇ 0.01), and 21.65% (p ⁇ 0.01), respectively. There was also a significant difference between the human urinary kininogenase II group and the oral group (p ⁇ 0.05).
- Sham operation group sublingual intravenous injection of normal saline
- Middle cerebral artery occlusion group intravenous saline
- Determination of cerebral infarction area The fully excised brain was placed in a small cup of saline containing a refrigerator at 4 ° C. After 10 minutes, the olfactory bulb, cerebellum and lower brain stem were removed, and five slices were cut along the coronal plane. In a tetrazolium (TTC) staining solution, incubate in a 37 ° C water bath for 30 minutes in the dark. Remove the brain slices and place them in 10% formalin. The normal tissue is rose red; the ischemic tissue is white. The area of the blood loss was measured by the weight accumulation method, and the percentage of the ischemic area to the total brain area was calculated.
- TTC tetrazolium
- Neurological symptom score judgment methods and criteria :
- the perfect score is 10 points. The higher the score, the more severe the brain dysfunction.
- Intravenous injection of human urokininogenase 30 minutes after middle cerebral artery occlusion in the drug-administered group can alleviate cerebral ischemia, cerebral edema and neurobehavioral symptoms caused by middle cerebral artery occlusion in rats, and has a dose-effect relationship;
- the positive control group (nimodipine) also has a good therapeutic effect.
- the invention is further illustrated by the following examples.
- the fresh male urine was ultrafiltered with water to a buffer of not less than 0.05 M Na2HP04-NaH2PO4, O.lM NaCl, pH 7.4 using an ultrafiltration membrane of 10,000 Da.
- the DEAE-Sepharose column was equilibrated with 0.05 M Na2HP04-NaH2P04, 0.1 M NaCl, pH 7.4 buffer.
- the concentrated urine was applied to a DEAE-Sepharose column, rinsed with equilibration buffer, and eluted with a buffer of 0.05 M Na2HP04-NaH2P04, 0.3 M NaCl, pH 7.4, and the eluted peak was collected.
- the Aprotinin-Sepharose column was equilibrated with 0.05 M Na2HP04-NaH2P04, pH 8.0 equilibration buffer.
- the DEAE-Sepharose column was eluted to pH 8.0 and applied to an Aprotinin-Sepharose column. Rinse with equilibration buffer and use 0.1 M HAc- NaAc, pH 4.0 buffer was eluted and the elution peak was collected.
- the eluted peak of Aprotinin-Sepharose column was dialyzed against 0.05 M Na2HP04-NaH2P04, 0.1 M NaCl, pH 7.0 buffer for 8 hours, heated in a constant temperature water bath at 60 ° C for 10 hours, and concentrated by ultrafiltration.
- the Sephadex G-100 column was equilibrated with physiological saline, and a human urokininogenase solution heated at 60 ° C for 10 hours was eluted on a Sephadex G-100 column, physiological saline, and the eluted peak was collected.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003234976A AU2003234976A1 (en) | 2002-05-13 | 2003-05-12 | The use of the human urinary kininogenase in the manufacture of a medicine for treating and preventing cerebral embolism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021167834A CN1183966C (zh) | 2002-05-13 | 2002-05-13 | 人尿激肽原酶在制备治疗和预防脑梗塞药物中的应用 |
CN02116783.4 | 2002-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003094935A1 true WO2003094935A1 (fr) | 2003-11-20 |
Family
ID=4744233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000345 WO2003094935A1 (fr) | 2002-05-13 | 2003-05-12 | Utilisation de la kininogenase urinaire humaine dans la fabrication d'un medicament pour le traitement et la prevention de l'embolie cerebrale |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1183966C (zh) |
AU (1) | AU2003234976A1 (zh) |
WO (1) | WO2003094935A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292793C (zh) * | 2004-11-03 | 2007-01-03 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备脓毒症药物中的应用 |
CN1308035C (zh) * | 2004-11-03 | 2007-04-04 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备急性冠脉疾病药物中的应用 |
CN1318090C (zh) * | 2004-11-29 | 2007-05-30 | 广东天普生化医药股份有限公司 | 一种用于提高人尿激肽原酶稳定性的药物组合物 |
CN100388950C (zh) * | 2006-09-05 | 2008-05-21 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备治疗糖尿病合并脑梗死药物中的应用 |
CN101134106B (zh) * | 2007-07-02 | 2012-01-11 | 广东天普生化医药股份有限公司 | 一种用于治疗脑梗塞的含有人尿激肽原酶的药物组合物 |
CN101134105B (zh) * | 2007-07-02 | 2011-04-20 | 广东天普生化医药股份有限公司 | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物组合物 |
CN101134953B (zh) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | 重组人胰激肽原酶 |
WO2009039704A1 (fr) * | 2007-09-27 | 2009-04-02 | Shanghai Wanxing Biopharmaceuticals, Co., Ltd. | Procédé de fabrication de kallikréine 1 humaine |
CN101879309A (zh) * | 2010-06-13 | 2010-11-10 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备治疗糖尿病足药物中的应用 |
CN101879308B (zh) * | 2010-06-13 | 2012-04-18 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备治疗急性肾衰药物中的应用 |
CN101879310A (zh) * | 2010-06-13 | 2010-11-10 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备治疗糖尿病肾病药物中的应用 |
CN108969758B (zh) * | 2018-09-07 | 2020-03-24 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备治疗血栓闭塞性脉管炎药物中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0546533A2 (en) * | 1991-12-10 | 1993-06-16 | Sanwa Kagaku Kenkyusho Co., Ltd. | Medical use of kininogenase |
-
2002
- 2002-05-13 CN CNB021167834A patent/CN1183966C/zh not_active Expired - Lifetime
-
2003
- 2003-05-12 WO PCT/CN2003/000345 patent/WO2003094935A1/zh not_active Application Discontinuation
- 2003-05-12 AU AU2003234976A patent/AU2003234976A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0546533A2 (en) * | 1991-12-10 | 1993-06-16 | Sanwa Kagaku Kenkyusho Co., Ltd. | Medical use of kininogenase |
Non-Patent Citations (1)
Title |
---|
HIROSHI NAGANO ET AL.: "Effects of a human urinary kininogenase(SK-827) on cerebral microcirculation after glass bead-induced cerebral embolism in rabbits", IN VIVO, vol. 6, no. 5, 1992, pages 497 - 502 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003234976A1 (en) | 2003-11-11 |
CN1403156A (zh) | 2003-03-19 |
CN1183966C (zh) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4708949A (en) | Therapeutic composition from plant extracts | |
US4795742A (en) | Therapeutic composition from plant extracts | |
AU652992B2 (en) | Method and composition for treating reperfusion injury | |
WO2003094935A1 (fr) | Utilisation de la kininogenase urinaire humaine dans la fabrication d'un medicament pour le traitement et la prevention de l'embolie cerebrale | |
EP0082731A1 (en) | The use of peptides as medicaments | |
WO2019206159A1 (zh) | 绿原酸及其组合物在制备治疗肉瘤的药物中的用途 | |
KR20090095668A (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
US5021239A (en) | Use of M-CSF to improve lipoprotein cholesterol profiles | |
WO1993008821A1 (en) | Side effect inhibitor for cancer therapy | |
Ter Borg et al. | Use of sodium hydroxide solution to clear partially occluded vascular access ports | |
JPS6237615B2 (zh) | ||
WO1998024467A1 (fr) | Medicaments contre l'hepatite fulminante | |
KR20050048940A (ko) | 마그네슘화합물 및/또는 마그네슘염을 포함하는 성기능장애 개선용 조성물 | |
US20070275086A1 (en) | Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy | |
JP2907603B2 (ja) | 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品 | |
Gutman et al. | Renin-like activity of the rat submaxillary gland: characterization and the effect of several drugs and stimuli | |
WO2005017139A1 (fr) | Thrombine provenant de venin de agkistrodon acutus utilisee comme medicament pour traiter une hemorragie | |
CN115624522B (zh) | 一种能够预防肺动脉压急性增高的载药乙醇注射液及其制备方法与应用 | |
RU2806093C1 (ru) | Применение икаритина для получения лекарственных средств | |
US3282782A (en) | Method of relieving pain in cancer by injecting lysozyme free of proteinaceous impurities | |
JPH08109140A (ja) | 高血圧症予防治療剤 | |
CN109276704A (zh) | 蜂毒肽在制备治疗和/或预防糖尿病的药物或保健品中的用途 | |
CA3171287A1 (en) | Medical use of icaritin | |
JPH07316072A (ja) | 妊娠中毒症治療剤 | |
JPH0867636A (ja) | 播種性血管内凝固症候群(dic)の予防治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |